HIGHLY ACTIVE ANTIRETROVIRAL THERAPY W/WO RHIL 2 FOR HIV POSITIVE PATIENTS

针对 HIV 阳性患者的高活性抗逆转录病毒治疗（含 RHIL 2）

• 批准号: 6413658
• 负责人: RICHARD B POLLARD
• 金额: $ 27.93万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-12-01 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6413658
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; clinical research; clinical trial phase I; combination chemotherapy; drug administration routes; drug resistance; drug screening /evaluation; human subject; human therapy evaluation; immunotherapy; interleukin 2; intravenous administration; phenotype; quality of life; virus load; virus replication

The purpose of this research study is to determine the safety, tolerance and effectiveness of Interleukin-2 (IL-2) in combination with highly active antiretroviral therapy (HAART), drugs that fight HIV, compared to HAART alone and to determine the best route of giving IL-2 in combination with this antiretroviral therapy. HAART is being given for its effectiveness to fight HIV infection and consists of one of the four combinations of drugs plus indinavir: ZDV + 3tc; ZDV+ddI; d4T+3TC; or d4T+ddI. IL-2 is an important substance which is naturally produced by the body's CD4 cells. People with HIV do not produce enough IL-2. IL-2 is being tested to see if it will increase the number of CD4 cells and boost the immune system.

本研究的目的是确定白细胞介素-2（IL-2）与高效抗逆转录病毒疗法（HAART），抗艾滋病毒药物相结合的安全性，耐受性和有效性，与HAART单独相比，并确定IL-2与这种抗逆转录病毒疗法相结合的最佳途径。 HAART因其有效对抗HIV感染而被给予，由四种药物组合之一加上茚地那韦组成：ZDV +3 tc; ZDV+ddI; d4 T +3 TC;或d4 T +ddI。 IL-2是一种重要的物质，由人体的CD 4细胞自然产生。 HIV感染者不能产生足够的IL-2。 目前正在测试IL-2是否会增加CD 4细胞的数量并增强免疫系统。